These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1359231)

  • 41. Toward an antibody-based HIV-1 vaccine.
    Hoxie JA
    Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [HIV antibody reaction caused by poliovirus].
    Fortschr Med; 1989 Jul; 107(22):12-3. PubMed ID: 2793021
    [No Abstract]   [Full Text] [Related]  

  • 43. Antibody B cell responses in HIV-1 infection.
    Mouquet H
    Trends Immunol; 2014 Nov; 35(11):549-61. PubMed ID: 25240985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The antibody response in HIV-1 infection.
    Burton DR; Montefiori DC
    AIDS; 1997; 11 Suppl A():S87-98. PubMed ID: 9451972
    [No Abstract]   [Full Text] [Related]  

  • 46. Negative results of a rapid antibody test for HIV in a 16-month-old infant with AIDS.
    Zhang Y; Wang J; Wilson GJ; Tang YW; Lu HZ
    Ann Clin Lab Sci; 2008; 38(3):293-5. PubMed ID: 18715861
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-1 cross-neutralizing antibodies in German HIV-1-infected patients do not correlate with an antibody-binding pattern against different HIV-1 isolates.
    Jurkiewicz E; Petry H; Sutor GC; Lang S; Schedel I; Hunsmann G
    AIDS; 1995 Jan; 9(1):91-3. PubMed ID: 7893448
    [No Abstract]   [Full Text] [Related]  

  • 48. A rapid ultrasound particle agglutination method for HIV antibody detection: Comparison with conventional rapid HIV tests.
    Bystryak S; Ossina N
    J Virol Methods; 2017 Nov; 249():38-47. PubMed ID: 28843787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes.
    van Montfort T; Nabatov AA; Geijtenbeek TB; Pollakis G; Paxton WA
    J Immunol; 2007 Mar; 178(5):3177-85. PubMed ID: 17312166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparative study of 8 combined HIV-1,2-antibody tests].
    Knödler B; Kühnl P; Roos D; Couroucé AM
    Beitr Infusionsther; 1991; 28():9-12. PubMed ID: 1725666
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Particle agglutination test: a new technic for the detection of HIV-1 antibodies].
    Müller F; Gromm M; Müller KH
    Immun Infekt; 1988 Aug; 16(4):148-51. PubMed ID: 3053422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
    Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epitopes of HIV-1 glycoproteins recognized by the human immune system.
    Laal S; Zolla-Pazner S
    Chem Immunol; 1993; 56():91-111. PubMed ID: 7680869
    [No Abstract]   [Full Text] [Related]  

  • 54. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
    Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
    EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.
    Smith DM; Strain MC; Frost SD; Pillai SK; Wong JK; Wrin T; Liu Y; Petropolous CJ; Daar ES; Little SJ; Richman DD
    Virology; 2006 Nov; 355(1):1-5. PubMed ID: 16962152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Origins of a Vaccine-Induced, Human Anti-HIV-1 Antibody.
    Julien JP
    EBioMedicine; 2015 Jul; 2(7):632-3. PubMed ID: 26288832
    [No Abstract]   [Full Text] [Related]  

  • 57. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Spear GT; Takefman DM; Sharpe S; Ghassemi M; Zolla-Pazner S
    Virology; 1994 Nov; 204(2):609-15. PubMed ID: 7941328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection.
    Björling E; Scarlatti G; von Gegerfelt A; Albert J; Biberfeld G; Chiodi F; Norrby E; Fenyö EM
    Virology; 1993 Mar; 193(1):528-30. PubMed ID: 8438591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Research. 'Superinfected' have more potent antibody response to HIV.
    AIDS Policy Law; 2012 May; 27(6):3. PubMed ID: 22655314
    [No Abstract]   [Full Text] [Related]  

  • 60. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41.
    Burrer R; Haessig-Einius S; Aubertin AM; Moog C
    Virology; 2005 Mar; 333(1):102-13. PubMed ID: 15708596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.